Is 4D Molecular Therapeutics Inc (FDMT) overvalued? · rev $37.0K
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
This page asks whether 4D Molecular Therapeutics Inc (FDMT) looks expensive on cached numbers — not a short thesis.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
FDMT currently screens at market cap $518.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next FDMT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the FDMT stock page for the full model, not this heading.
Not investment advice.